Announced
Financials
Sources
Tags
Friendly
Cross Border
Biotechnology
biotechnology company
clinical stage pharmaceuticals
Germany
Pending
Minority
Acquisition
Single Bidder
Private
Synopsis
Pfizer, a biopharmaceutical company, agreed to invest $185m in BioNTech, a manufacturer of active immunotherapies. “We have already started working with Pfizer on our COVID-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” Ugur Sahin, BioNTech Co-Founder and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.